Agios Pharmaceuticals (NASDAQ:AGIO) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a report published on Saturday.

AGIO has been the topic of a number of other reports. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank raised their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $59.02 on Friday. Agios Pharmaceuticals has a 12-month low of $20.40 and a 12-month high of $62.58. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of 5.20 and a beta of 0.75. The business has a 50 day simple moving average of $45.73 and a 200 day simple moving average of $43.45.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Charles Schwab Investment Management Inc. boosted its position in shares of Agios Pharmaceuticals by 1.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock worth $20,687,000 after buying an additional 8,093 shares during the period. Intech Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals in the third quarter worth $892,000. Quest Partners LLC raised its holdings in shares of Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,283 shares in the last quarter. Atria Investments Inc raised its holdings in shares of Agios Pharmaceuticals by 47.4% during the third quarter. Atria Investments Inc now owns 10,628 shares of the biopharmaceutical company’s stock worth $472,000 after acquiring an additional 3,418 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its position in Agios Pharmaceuticals by 19.3% during the third quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock valued at $1,737,000 after purchasing an additional 6,320 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.